HCM
IMMU

Highbridge Capital Management’s Immunomedics Inc IMMU Stock Holding History

Highbridge Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-739,371
Closed -$10.3M – 2113
2017
Q3 		$10.3M Buy
+739,371
New +$7.37M 0.15% 163
2017
Q2 		– Sell
-77,740
Closed -$546K – 1757
2017
Q1 		$503K Buy
+77,740
New +$394K 0.01% 904
2015
Q1 		– Sell
-23,334
Closed -$112K – 1665
2014
Q4 		$112K Sell
23,334
-19,932
-46% -$78.8K ﹤0.01% 1104
2014
Q3 		$161K Buy
+43,266
New +$146K ﹤0.01% 1117
2014
Q1 		– Sell
-21,590
Closed -$99K – 1313
2013
Q4 		$99K Buy
+21,590
New +$96.1K ﹤0.01% 1006

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Highbridge Capital Management's IMMU Position: Q4 2017 in Review

Highbridge Capital Management sold out of Immunomedics Inc (IMMU) in Q4 2017, closing a stake of 739,371 shares — an estimated $10.3M sold.

Highbridge Capital Management first reported a position in IMMU in Q4 2013 and held it in 5 quarters. The position peaked at $10.3M in Q3 2017. 157 funds tracked by Wall St. Rank hold IMMU as of Q4 2017.

  • Highbridge Capital Management reported no remaining Immunomedics Inc position as of Q4 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 739,371 Immunomedics Inc shares in Q4 2017, an estimated $10.3M.
  • Highbridge Capital Management first reported a position in Immunomedics Inc in Q4 2013 and held it in 5 quarters.
  • Highbridge Capital Management's Immunomedics Inc position peaked at $10.3M in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.